PARTICIPANTS NEEDED

Study 20120102  A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1

This study is evaluating brodalumab, an investigational medication that is being studied for the treatment of plaque psoriasis. Brodalumab is a type of protein that blocks the interaction of other proteins in the body that can cause inflammation and symptoms related to psoriasis. This study will see if brodalumab is effective in treating participants with moderate to severe plaque psoriasis and whether it causes any side effects compared to placebo. If treatment with brodalumab makes your psoriasis better, this study may also test how long you stay better if you stop taking brodalumab. Your participation may last up to 5 years.

You must meet the following criteria to become a study participant:

- Be 18 to 75 years of age
- Have moderate to severe plaque psoriasis requiring treatment
- Are not pregnant or breastfeeding and are willing to avoid pregnancy during the study
- Be available for frequent clinic visits approximately 2-3 times a month for the first 24 months, then every 1-3 months
- Meet other entry criteria based on screening examinations

You may receive the following:

- Study Medication
- Study required physical exams and laboratory tests
- Compensation for time and travel

For more information contact:
Rosemary King, P.A.-C.
Clinical Research Coordinator
(314) 256-3436
kingrm@slu.edu

Saint Louis University IRB #22230; Approved 01/21/2013; Board #1